Business Context and Reporting Period
This Form 8-K is a current report filed by Conversion Labs, Inc. (not Lifemd, Inc.) on October 22, 2020, covering events occurring on October 16, 2020, and October 21, 2020. The company operates a telemedicine platform and is incorporated in Delaware.
Key Financial Metrics
The filing does not provide specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The report focuses on corporate governance and equity transactions rather than financial performance.
Material Changes and Corporate Actions
- Unregistered Equity Issuance: On October 16, 2020, the Company issued 800,000 shares of restricted common stock to Blue Horizon Consulting, LLC (owned by director Happy Walters) for achieving specified revenue targets under a consulting agreement. An additional 1,200,000 shares may be issued upon achieving further milestones.
- Board Appointment: On October 21, 2020, Dr. Eleanor C. Mariano was appointed to the Board of Directors. She received a one-time grant of 20,000 shares of common stock as compensation.
- Board Resignation: On October 21, 2020, Anthony Bruzzese resigned from the Board of Directors effective immediately. The resignation was not due to any disagreement with the Company.
Guidance, Outlook, and Risks
Management commentary indicates that Dr. Mariano's background in internal medicine and concierge care is intended to lead the Company toward continued growth with its telemedicine platform. The filing notes that the equity issuances were exempt from registration under Section 4(a)(2) of the Securities Act. No specific financial guidance or forward-looking revenue projections are included in this document.
Investor Verification Checklist
- Verify the exact number of shares issued to Blue Horizon Consulting and the specific revenue targets required for the potential issuance of the additional 1,200,000 shares.
- Confirm the vesting schedule or restrictions applicable to the 20,000 Director Shares granted to Dr. Mariano.
- Review the full text of the Director Agreement (Exhibit 10.1) for complete terms of Dr. Mariano's compensation and obligations.
- Check subsequent filings for any financial impact of the equity issuances on share count and dilution.